JP5912023B2 - Antibacterial peptide secretion inducer - Google Patents

Antibacterial peptide secretion inducer Download PDF

Info

Publication number
JP5912023B2
JP5912023B2 JP2011215774A JP2011215774A JP5912023B2 JP 5912023 B2 JP5912023 B2 JP 5912023B2 JP 2011215774 A JP2011215774 A JP 2011215774A JP 2011215774 A JP2011215774 A JP 2011215774A JP 5912023 B2 JP5912023 B2 JP 5912023B2
Authority
JP
Japan
Prior art keywords
asg
brown rice
defensin
antibacterial
antibacterial peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011215774A
Other languages
Japanese (ja)
Other versions
JP2013074821A (en
Inventor
翔太 野中
翔太 野中
喜瀬 光男
光男 喜瀬
時芳 綾部
時芳 綾部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fancl Corp
Original Assignee
Fancl Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fancl Corp filed Critical Fancl Corp
Priority to JP2011215774A priority Critical patent/JP5912023B2/en
Publication of JP2013074821A publication Critical patent/JP2013074821A/en
Application granted granted Critical
Publication of JP5912023B2 publication Critical patent/JP5912023B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Description

本発明は、抗菌性ペプチドの分泌誘導剤に関する。   The present invention relates to an antibacterial peptide secretion inducer.

細菌感染症や真菌感染症は人類の寿命を左右する大きな疾患であり、抗生物質や合成抗菌剤など種々の薬剤が開発されてきた。しかし抗生物質や抗菌剤は常に抵抗性微生物が出現する。ひとたびこのような抗生物質耐性菌が出現すると、従来の抗菌剤では治療の手段がなく、耐性菌に対する対策は新たな抗菌剤を開発するしかなかった。
近年高齢者の間で、免疫の低下に伴う常在菌による感染症が問題となっている。常在菌は所謂多剤耐性株が多く、いったん老人介護施設などで多剤耐性菌の感染患者が発生すると効果的な治療手段がなく、施設内で多数の患者が連鎖的に発生し、状況によっては施設の閉鎖や患者の隔離などが必要になってくる。このため、多剤耐性菌に対する対策は大きな社会問題となっている。
このため、インターフェロン類やインターロイキン類の分泌を誘導する多糖や糖タンパク質などを投与して生体の免疫システムを増強する治療や予防方法が提案されているが、あまり効果はあがっていない。
ところで動物、植物、昆虫、酵母、乳酸菌などのさまざまな生物には、外界からの病原微生物の侵入に対して自己防御するための自己生体防御機構が本来備っている。このような外来からの進入を防御するために、アミノ酸が10数個〜50数個程度からなる抗菌ペプチドを生物自らが産生していることが明らかになっている。これらの抗菌ペプチドは、細菌、真菌などに対してはば広い範囲の抗菌スペクトルを有しているとともに、生物自らが産生していることから生体に対しては副作用も阻害作用も有していない。
Bacterial infections and fungal infections are major diseases that affect the longevity of mankind, and various drugs such as antibiotics and synthetic antibacterial agents have been developed. However, antibiotics and antibacterial agents always show resistant microorganisms. Once such antibiotic-resistant bacteria emerged, conventional antibacterial agents had no means of treatment, and the only countermeasures against resistant bacteria were to develop new antibacterial agents.
In recent years, infectious diseases caused by resident bacteria associated with decreased immunity have become a problem among the elderly. There are many so-called multi-drug-resistant strains, and once a multi-drug-resistant bacterial infection occurs in a nursing home for the elderly, there is no effective means of treatment. Depending on the situation, it may be necessary to close the facility or isolate the patient. For this reason, measures against multidrug-resistant bacteria have become a major social problem.
For this reason, treatment and prevention methods have been proposed in which polysaccharides or glycoproteins that induce secretion of interferons or interleukins are administered to enhance the immune system of the living body, but the effect is not so high.
By the way, various organisms such as animals, plants, insects, yeasts, and lactic acid bacteria are originally equipped with a self-biological defense mechanism for self-protection against the invasion of pathogenic microorganisms from the outside world. In order to prevent such invasion from outside, it has been revealed that organisms themselves produce antibacterial peptides consisting of about 10 to 50 or more amino acids. These antibacterial peptides have a wide range of antibacterial spectrum against bacteria, fungi, etc., and have no side effects or inhibitory effects on living organisms because they are produced by living organisms themselves. .

このような抗菌ペプチドのうち、ヒト由来の抗菌ペプチドとしては、例えば、ディフェンシン・ファミリー(α−ディフェンシン、β−ディフェンシン等)、カセリシジン(LL-37)、ダームシジン(dermcidin)、LEAP-1(ヘプシジン)、LEAP-2などが知られている。また、ウシ好中球から単離された、トリプトファンリッチな13アミノ酸からなる広域スペクトル抗菌活性を示す抗菌ペプチドであるインドリシジンの類似体の合成カチオン性抗菌ペプチド、オミガナン(Ominagan pentahydrochloride) が、カテーテル用局所感染予防薬として開発されている(例えば、非特許文献1参照)。さらに、乳酸菌が産生する抗菌ペプチドであるナイシンが、食品添加物としてすでに使用されている。   Among these antibacterial peptides, human-derived antibacterial peptides include, for example, the defensin family (α-defensin, β-defensin, etc.), cathelicidin (LL-37), darmcidin, LEAP-1 (hepcidin) LEAP-2 and the like are known. In addition, Ominagan pentahydrochloride, a synthetic cationic antimicrobial peptide of an analog of indolicidin, which is an antimicrobial peptide consisting of 13 amino acids rich in tryptophan isolated from bovine neutrophils and exhibits a broad spectrum antimicrobial activity, It has been developed as an infection prevention drug (see Non-Patent Document 1, for example). Furthermore, nisin, an antimicrobial peptide produced by lactic acid bacteria, has already been used as a food additive.

この抗菌ペプチドを人為的に人に発現増強または分泌促進することができれば多剤耐性菌などの感染により一層大きな効果が期待できる。このような技術として、例えば、有機酸をヒトβ−ディフェンシンの分泌促進剤の有効成分として使用する技術(特許文献1)、酵母由来の多糖類含有組成物によってディフェンシン遺伝子を発現誘導する技術(特許文献2)、酵母由来の不溶性画分によってディフェンシン遺伝子を発現誘導する技術(特許文献3)、酵母由来のマンナン含有成分を用いて抗菌ペプチドを発現誘導する技術(特許文献4)、イソロイシン、ロイシンまたはバリンから選ばれた分岐鎖必須アミノ酸の有効成分による抗菌ペプチドの発現誘導に関する技術(特許文献5)、ヨーグルト、甘酒の抽出物、焼酎もろみ、糠味噌濃縮物などの有効成分を使用した抗菌ペプチドの発現誘導技術(特許文献6)などが提案されている。
現在も日常で簡便に使用できる抗菌ペプチドの誘導剤の探索が行われている。
If this antibacterial peptide can be artificially enhanced or secreted by humans, a greater effect can be expected by infection with multidrug-resistant bacteria. As such a technique, for example, a technique using an organic acid as an active ingredient of a human β-defensin secretion promoter (Patent Document 1), a technique for inducing expression of a defensin gene using a yeast-containing polysaccharide-containing composition (patent) Document 2), a technique for inducing expression of a defensin gene using an insoluble fraction derived from yeast (Patent Document 3), a technique for inducing expression of an antibacterial peptide using a mannan-containing component derived from yeast (Patent Document 4), isoleucine, leucine or Expression of antibacterial peptides using active ingredients such as yogurt, amazake extract, shochu mash, and miso concentrate A guidance technique (Patent Document 6) has been proposed.
Currently, the search for an inducer of an antibacterial peptide that can be easily used in daily life is being conducted.

国際公開第2005/027893号International Publication No. 2005/027893 特開2003−197号公報Japanese Patent Laid-Open No. 2003-197 特開2003−262号公報JP 2003-262 A 特開2006−241023号公報JP 2006-241023 A 特開2003−95938号公報JP 2003-95938 A 特開2005−270117号公報JP-A-2005-270117

Selsted, et al.; J.Biol.Chem.267:4292,1992Selsted, et al .; Biol. Chem. 267: 4292, 1992

本発明は、ヒトに備わっている自己生体防御機構を発揮する抗菌性ペプチドの一種であるα−ディフェンシン等の抗菌性ペプチドの誘導剤を提供することを課題とする。   An object of the present invention is to provide an inducer of an antibacterial peptide such as α-defensin, which is a kind of antibacterial peptide that exhibits a self-biodefense mechanism provided in humans.

すなわち、本発明の主な構成は、次のとおりである。
(1)発芽玄米及び/又は玄米糠由来のステロール配糖体を有効成分とするディフェンシンの誘導剤(食品、食品添加物、ペット用飼料の添加剤の用途を除く)。
That is, the main configuration of the present invention is as follows.
(1) A defensin inducer comprising a germinated brown rice and / or sterol glycoside derived from brown rice bran as an active ingredient (except for food, food additives, and pet feed additives).

この発明に係る抗菌ペプチドの発現誘導剤または分泌促進剤は、経口投与によって腸管内に抗菌ペプチドの発現を誘導または分泌を促進できることから、医薬、飲食品、ペット用飼料して使用できるという効果がある。   Since the antibacterial peptide expression inducer or secretion enhancer according to the present invention can induce or promote the expression of the antibacterial peptide in the intestinal tract by oral administration, it has the effect that it can be used as a medicine, food or drink, and pet feed. is there.

本発明による抗菌性ペプチドの分泌促進効果を示すグラフThe graph which shows the secretion promotion effect of the antimicrobial peptide by this invention

本発明に使用する発芽玄米及び/又は玄米から抽出されたステロール配糖体画分(以下「ASG」と称する場合がある)は、発芽玄米及び/又は玄米から得た糠をヘキサンで中性脂質を除去し、得られた残渣をさらに有機溶媒にて抽出した脂質画分に含まれ、高速液体クロマトグラフィー(HPLC)で分離・濃縮することが出来る。
本発明は、この発芽玄米及び/又は玄米由来のステロール配糖体を有効成分とするα−ディフェンシン誘導剤である。摂取方法は、経口、注射により行うことができ、医薬、飲食品、食品添加剤、ペット用の医薬剤、ペット用飼料の添加剤として活用することができる。通常食用にしている発芽玄米及び/又は玄米由来の成分であるので、安全性が高い。
ASGは、発芽玄米及び/又は玄米の糠成分から極微量抽出される成分であるので、ASGを医薬 あるいは飲食品、ペット用医薬や飼料に応用する場合は、抽出されたASGそのものを使用する。発芽玄米及び/又は玄米そのものあるいは発芽玄米及び/又は玄米の粉末などASGを抽出する前の状態で使用することは発明の対象外である。
Germinated brown rice and / or sterol glycoside fraction extracted from brown rice used in the present invention (hereinafter sometimes referred to as “ASG”) is a neutral lipid obtained from germinated brown rice and / or brown rice with hexane. The residue obtained is further contained in a lipid fraction extracted with an organic solvent, and can be separated and concentrated by high performance liquid chromatography (HPLC).
The present invention is an α-defensin inducer containing the germinated brown rice and / or sterol glycoside derived from brown rice as an active ingredient. The ingestion method can be performed orally or by injection, and can be used as an additive for pharmaceuticals, foods and drinks, food additives, pet pharmaceuticals, and pet feeds. Since it is a component derived from germinated brown rice and / or brown rice, which is usually used for food, safety is high.
Since ASG is a very small amount extracted from germinated brown rice and / or rice bran components, the extracted ASG itself is used when ASG is applied to medicine, food and drink, pet medicine and feed. Use of germinated brown rice and / or brown rice per se or germinated brown rice and / or powder of brown rice prior to extraction of ASG is out of the scope of the invention.

本発明は、α−ディフェンシン等の抗菌性ペプチドの誘導剤、 食品添加物、食品およびペットフード、動物用医薬として利用することができる。剤型は、公知の方法により助剤とともに任意の形態に製剤化して、経口摂取(投与)することができる。カプセル剤又は錠剤、顆粒剤、細粒剤、散剤、液状として摂取(投与)できる。
摂取(投与)量は、摂取(投与)方法と、対象者の年齢、病状や一般状態等によって変化し得るが、成人では体重1kg当たり通常、1日当たり有効成分として0.1〜600mgが適当である。
The present invention can be used as an inducer of antibacterial peptides such as α-defensin, food additives, foods and pet foods, and veterinary drugs. The dosage form can be formulated into an arbitrary form together with an auxiliary agent by a known method and taken orally (administered). It can be ingested (administered) as a capsule or tablet, granule, fine granule, powder, or liquid.
The ingestion (administration) amount may vary depending on the ingestion (administration) method and the age, medical condition, general condition, etc. of the subject, but in adults, 0.1 to 600 mg as an active ingredient per day is usually appropriate per 1 kg of body weight.

本発明のα−ディフェンシン等抗菌性ペプチドの誘導剤は、一般食品や健康食品に配合することができ、また、食品添加物の成分とすることもできる。配合する食品は特に限定されず、例えば食パン、菓子パン、パイ、デニッシュ、ドーナツ、ケーキ等のベーカリー食品、うどん、そば、中華麺、焼きそば、パスタ等の麺類、天ぷら、コロッケ等のフライ類、カレー、シチュー、ドレッシング等のソース類、ふりかけ類、かまぼこ等の練り製品、ジュース等の飲料、スナック菓子、米菓、飴、ガム等の菓子類を挙げることができる。
ペットには、犬、猫、ハムスター、リス等の哺乳類の飼料として適している。本発明のペットフードの形態は特に限定されるものではなく、例えばドライタイプ、ウェットタイプ、セミモイストタイプ、ビスケットタイプ、ソーセージタイプ、ジャーキータイプ、粉末、顆粒、カプセルなどが挙げられる。
The inducer of antibacterial peptides such as α-defensin of the present invention can be incorporated into general foods and health foods, and can also be used as a component of food additives. The food to be blended is not particularly limited, for example, bakery foods such as bread, confectionery bread, pies, Danish, donuts, cakes, noodles such as udon, soba, Chinese noodles, yakisoba, pasta, fries such as tempura, croquettes, curry, Sources such as stew and dressing, sprinkles, kneaded products such as kamaboko, beverages such as juice, snacks, rice confectionery, rice cake, confectionery such as gum.
Suitable for pets as feed for mammals such as dogs, cats, hamsters and squirrels. The form of the pet food of the present invention is not particularly limited, and examples thereof include dry type, wet type, semi-moist type, biscuit type, sausage type, jerky type, powder, granule, capsule and the like.

<発芽玄米及び又は玄米由来のステロール配糖体>
1.糠成分を採取する発芽玄米は、公知の方法により調製することができる。本出願人は、発芽玄米について多数の提案をしており、例えば、特許第3423927号公報、特許第3611804号公報、特許第3738025号公報等に開示された発芽玄米の製法によって得ることができる。
発芽玄米及び/又は玄米を5〜15%程度搗精して糠成分を採取する。この糠成分を最初に、ヘキサンにて脱脂する。この脱脂工程は、一般の糠を脱脂して米糠油を採取する方法と同様である。本発明では、この脱脂糠を原料として、さらに、有機溶媒を用いてステロール配糖体画分を抽出する。
<Sprouted brown rice and / or sterol glycoside derived from brown rice>
1. Germinated brown rice from which the koji component is collected can be prepared by a known method. The present applicant has made a number of proposals for germinated brown rice, which can be obtained, for example, by the method for producing germinated brown rice disclosed in Japanese Patent No. 3423927, Japanese Patent No. 3611804, Japanese Patent No. 3738025, and the like.
The germinated brown rice and / or brown rice is refined by about 5 to 15% and the koji component is collected. The soot component is first degreased with hexane. This degreasing step is the same as the method for collecting rice bran oil by degreasing general rice bran. In the present invention, the sterol glycoside fraction is further extracted using this defatted koji as a raw material and using an organic solvent.

2.本願発明で使用するASGは、以下の化学式で特定されるステロール配糖体である。 2. ASG used in the present invention is a sterol glycoside specified by the following chemical formula.

(i) 一般式(1)中のXは以下の群から選択され、かつ、Yは5α-cholest-8(14)-en3β-olであるパルミチン酸(16:0)、ステアリン酸(18:0)、2-ヒドロキシ-オクタデカン酸(18:0 (2h))、オレイン酸(18:1)、リノール酸(18:2)、又は、リグノセリン酸(24:0)
(ii) 一般式(1)中のXは2-ヒドロキシ-オクタデカン酸(18:0 (2h))であり、かつ、Yは以下の群から選択されるCampesterol、Stigmasterol、5α-cholest-8(14)-en-3β-ol、又は、β-Sitosterol
(i) X in the general formula (1) is selected from the following group, and Y is 5α-cholest-8 (14) -en3β-ol: palmitic acid (16: 0), stearic acid (18: 0), 2-hydroxy-octadecanoic acid (18: 0 (2h)), oleic acid (18: 1), linoleic acid (18: 2), or lignoceric acid (24: 0)
(ii) X in the general formula (1) is 2-hydroxy-octadecanoic acid (18: 0 (2h)), and Y is Campesterol, Stigmasterol, 5α-cholest-8 ( 14) -en-3β-ol or β-Sitosterol

以下に実施例、試験例を示し、本発明をさらに説明する。
<ASGの調製例>
発芽玄米糠をヘキサンで脂質成分中の中性脂質を除去後、それぞれの残渣につき、ヘキサン、クロロホルム及びメタノールを用いてASGの粗抽出液を調製した。このASG粗抽出液からクロロホルム:メタノール(2:1)混合液で抽出し、シリカゲル担体カラムクロマトグラフィーによって、ASGの調製を行った。
試験に用いたASGの抽出は発芽玄米約2,000kgを搗精して得られた糠200kg(搗精度10%)を用いて行った。
米糠(500g)が浸る量のヘキサンを加え十分に撹拌した後ガーゼでろ過を行い、脱脂糠を得た。その後、ヘキサンを揮発させた脱脂糠を1.5 kgに対してクロロホルム:メタノール2:1を(3L)加えて総脂質画分を抽出し、抽出液をエバポレーターで乾固させ乾固物を得た。
The following examples and test examples further illustrate the present invention.
<Examples of ASG preparation>
After removing the neutral lipid in the lipid component from the germinated brown rice bran with hexane, a crude extract of ASG was prepared for each residue using hexane, chloroform and methanol. This ASG crude extract was extracted with a chloroform: methanol (2: 1) mixture, and ASG was prepared by silica gel carrier column chromatography.
The extraction of ASG used in the test was performed using 200 kg of koji (10% koji accuracy) obtained by scouring about 2,000 kg of germinated brown rice.
An amount of hexane soaked with rice bran (500 g) was added and stirred sufficiently, followed by filtration with gauze to obtain a defatted koji. Thereafter, the total fat fraction was extracted by adding chloroform: methanol 2: 1 (3 L) to 1.5 kg of defatted soot in which hexane was volatilized, and the extract was dried to dryness by an evaporator.

乾固物は300mlのクロロホルム:ヘキサン=1:1に溶解し、クロロホルムで膨潤させた直径10cm×長さ100cm(メルク社製シリカゲル60を80cm充填)のカラムに全溶解液をアプライした。溶液がイアトロビーズに全てしみ込んだ後、クロロホルム:ヘキサン=1:1(7,840ml)、クロロホルム(20,160ml)、クロロホルム:メタノール=9:1(10,080ml)の順でそれぞれを通液した。クロロホルム:メタノール=9:1の通液により分離した暗緑色の溶液だけを全て採取した。
採取した暗緑色の溶液はエバポレーターで乾固させ試験に供した。表1に各ポイントでの収量を示す。
The dried product was dissolved in 300 ml of chloroform: hexane = 1: 1, and the whole solution was applied to a column 10 cm in diameter and 100 cm in length (packed with 80 cm of Merck silica gel 60) swollen with chloroform. After all the solution had soaked into the Iatro beads, chloroform: hexane = 1: 1 (7,840 ml), chloroform (20,160 ml), chloroform: methanol = 9: 1 (10,080 ml) were passed in this order. Only a dark green solution separated by passing chloroform: methanol = 9: 1 was collected.
The collected dark green solution was dried to dryness using an evaporator. Table 1 shows the yield at each point.

<ASG分析>
抽出したASGの分析は以下の条件で行った。この分析の結果、最終乾固物には、ASGが72.6%含まれていることが判明した。
分析条件
検出器 :CoronaTM CADTM Charged Aerosol Detector
カラム :LiChrospher Si 60(5μm,125×4mm i.d.,Merck)
カラム温度:40度
流 速 :1mL/min.
注入量 :10μL
サンプル溶媒:クロロホルム:メタノール(2:1,vol/vol)
検量線濃度 :10,20,40,60及び80μg/mL
移動相、グラジェント条件(表2参照)
<ASG analysis>
The extracted ASG was analyzed under the following conditions. As a result of this analysis, the final dried product was found to contain 72.6% ASG.
Analysis conditions Detector: CoronaTM CADTM Charged Aerosol Detector
Column: LiChrospher Si 60 (5μm, 125 × 4mm id, Merck)
Column temperature: 40 degrees Flow rate: 1 mL / min.
Injection volume: 10μL
Sample solvent: chloroform: methanol (2: 1, vol / vol)
Calibration curve concentration: 10, 20, 40, 60 and 80 μg / mL
Mobile phase, gradient conditions (see Table 2)

<ディフェンシン誘導試験>
I.材料及び方法
特開2011−78318号公報に開示されているマウス小腸陰窩を用いたパネト細胞からのα−ディフェンシン分泌アッセイ系を用いてASGがパネト細胞から抗菌性ペプチドであるα−ディフェンシンの分泌誘導効果を抗菌活性を指標にして確認した。
1.小腸陰窩材料採取:
ICRマウス(日本チャールズ・リバー社)から、従来法に従ってクリプト(小腸陰窩)を含む小腸の組織を採取し、1mLのPBS(−)に懸濁して、クリプトを含む懸濁液を調製した{Ayabe Tら、Nature Immunol.第1巻、第113-118頁、2000年}。この懸濁液に含まれるクリプト数を血球計算盤(Burker−Turk;サンリード硝子社)を用いて数えたところ、5〜8×104個であった。また、位相差顕微鏡(オリンパス社)を用いて弱拡大視野で観察して、この懸濁液に含まれる組織のうちクリプトが占める割合を求めたところ、その割合は70%以上であった。
2. パネト細胞分泌反応およびex vivo殺菌アッセイ:
回収した小腸陰窩と上記のASG含有組成物をex vivo共培養して粗分泌物を回収した。ASGの濃度は生理食塩水を用いて1:10,000、1:1,000または1:100希釈とした。同時に小腸陰窩のASG非曝露のPBS対照上清も回収した。30%酢酸中でペプチドを抽出、透析に引き続いて真空凍結乾燥した。回収した分泌物および非曝露対照上清抽出物を1μLが小腸陰窩100個由来となるように純水に溶かした。 次に、分泌物のSalmonella Typhimurium phoP-に対する殺菌活性を解析した。
パネト細胞分泌物および非曝露対照上清、抽出物を1×106colony-forming units (CFU) のS. Typhimurium phoP-と37℃で60分反応させた後、TSAプレート上で一晩培養した。生存CFUをカウンし、殺菌率を図1に示した。
<Defensin induction test>
I. Materials and Methods JP using α- defensin secretion assay system from Paneto cells using mouse small intestinal crypts disclosed in 2011-78318 Patent Publication No. ASG is an antimicrobial peptide from the Paneto cells α- defensins the secretion-inducing effect of, was confirmed by the antibacterial activity as an index.
1. Small intestinal crypt material collection:
A small intestine tissue containing crypt (small intestine crypt) was collected from an ICR mouse (Nippon Charles River) according to a conventional method, and suspended in 1 mL of PBS (−) to prepare a suspension containing crypt { Ayabe T et al., Nature Immunol. Volume 1, pp. 113-118, 2000}. When the number of crypts contained in this suspension was counted using a hemocytometer (Burker-Turk; Sunreed Glass), it was 5 to 8 × 10 4 . Moreover, when the ratio which the cryptography occupied among the structures | tissues contained in this suspension was calculated | required by observing in a weak expansion visual field using a phase-contrast microscope (Olympus), the ratio was 70% or more.
2. Panetocyte secretion reaction and ex vivo bactericidal assay:
The recovered small intestine crypt and the above ASG-containing composition were co-cultured ex vivo to recover the crude secretion. The concentration of ASG was diluted 1: 10,000, 1: 1,000 or 1: 100 with physiological saline. At the same time, the ASG-unexposed PBS control supernatant of the small intestinal crypt was also collected. The peptide was extracted in 30% acetic acid and lyophilized following dialysis. The collected secretion and the unexposed control supernatant extract were dissolved in pure water so that 1 μL was derived from 100 small intestinal crypts. Next, the bactericidal activity of the secretion against Salmonella Typhimurium phoP- was analyzed.
Panetocyte secretion and unexposed control supernatant and extract were reacted with 1 × 10 6 colony-forming units (CFU) S. Typhimurium phoP- at 37 ° C for 60 minutes and then cultured on TSA plate overnight . Viable CFU was counted and the bactericidal rate is shown in FIG.

II.結果
ASGのパネト細胞からのα−ディフェンシン等の抗菌性ペプチド分泌誘導による S. Typhimurium phoP-に対するex vivoでの殺菌活性を解析した。ASGをマウス小腸陰窩に反応濃度および小腸陰窩数を変えて検討したところ、 図1に示すよう、ASG(1:10,000 〜1:100 )に暴露した小腸陰窩50個由来の分泌物はコントロールと比較して99%以上の有意な殺菌率を認めた。また、この殺菌活性はASGの濃度に依存性していた。小腸陰窩 100個由来の分泌物はASG(1:100)でさらに強力な殺菌活性を示した。
小腸陰窩200個および500個由来の分泌物では検討したすべてのASG濃度で細菌数が100分の1以下となった。
以上の結果より、ASGはマウス小腸パネト細胞からのαディフェンシン等抗菌性ペプチドによるex vivo殺菌活性放出を誘導することが明らかになった。また、その殺菌活性は ASG濃度依存性であることが確認できた。
II. result
Ex vivo bactericidal activity against S. Typhimurium phoP- by inducing secretion of antibacterial peptides such as α-defensin from ASG panel cells was analyzed. As shown in Fig. 1, secretions from 50 small intestinal crypts exposed to ASG (1: 10,000-1 : 100 ) were examined by changing the reaction concentration and number of small intestinal crypts in mouse small intestinal crypts. Compared with the control, a significant sterilization rate of 99% or more was recognized. This bactericidal activity was dependent on the concentration of ASG . Secretions from 100 small intestinal crypts showed stronger bactericidal activity with ASG (1: 100 ).
Secretions from 200 and 500 small intestinal crypts resulted in less than 1/100 bacterial count at all ASG concentrations examined.
From the above results, it was revealed that ASG induces ex vivo bactericidal activity release by antimicrobial peptides such as α-defensin from mouse small intestinal panel cells. In addition, it was confirmed that the bactericidal activity was ASG concentration-dependent.

以下に本発明のASGを用いた処方例を示す。
処方例1
[カプセル剤]
組成
ASG…100mg
ミツロウ…10mg
ぶどう種子オイル…110mg
上記成分を混合し、ゼラチンおよびグリセリンを混合したカプセル基剤中に充填し、軟カプセルを得た。
The prescription example using ASG of this invention is shown below.
Formulation Example 1
[Capsule]
Composition ASG ... 100mg
Beeswax ... 10mg
Grape seed oil ... 110mg
The above ingredients were mixed and filled into a capsule base mixed with gelatin and glycerin to obtain soft capsules.

処方例2
[錠剤]
組成
ASG乾固物…150mg
セルロース…80mg
デンプン…20mg
ショ糖脂肪酸エステル…2mg
上記成分を混合、打錠し、錠剤を得た。
Formulation example 2
[tablet]
Composition ASG dried product ... 150mg
Cellulose ... 80mg
Starch ... 20mg
Sucrose fatty acid ester ... 2mg
The above components were mixed and tableted to obtain tablets.

処方例3
[飲料]
(組 成) (配合;質量%)
果糖ブトウ糖液糖 5.00
クエン酸 10.4
L−アスコルビン酸 0.20
香料 0.02
色素 0.10
ASG乾固物 1.00
水 82.28
Formulation Example 3
[Beverages]
(Composition) (Composition: Mass%)
Fructose butter sugar liquid sugar 5.00
Citric acid 10.4
L-ascorbic acid 0.20
Perfume 0.02
Dye 0.10
ASG dried product 1.00
Water 82.28

Claims (1)

発芽玄米及び/又は玄米糠由来のステロール配糖体を有効成分とするディフェンシンの誘導剤(食品、食品添加物、ペット用飼料の添加剤の用途を除く)。 Defensin inducer containing germinated brown rice and / or sterol glycoside derived from brown rice bran as an active ingredient (excluding food, food additives and pet feed additives).
JP2011215774A 2011-09-30 2011-09-30 Antibacterial peptide secretion inducer Active JP5912023B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011215774A JP5912023B2 (en) 2011-09-30 2011-09-30 Antibacterial peptide secretion inducer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011215774A JP5912023B2 (en) 2011-09-30 2011-09-30 Antibacterial peptide secretion inducer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016071615A Division JP6093068B2 (en) 2016-03-31 2016-03-31 Antibacterial peptide secretion inducer

Publications (2)

Publication Number Publication Date
JP2013074821A JP2013074821A (en) 2013-04-25
JP5912023B2 true JP5912023B2 (en) 2016-04-27

Family

ID=48478849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011215774A Active JP5912023B2 (en) 2011-09-30 2011-09-30 Antibacterial peptide secretion inducer

Country Status (1)

Country Link
JP (1) JP5912023B2 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009110612A1 (en) * 2008-03-06 2009-09-11 株式会社ファンケル New compound derived from germinated brown rice, and agent containing said compound as an active ingredient for prevention or amelioration of neuropathy
JP2011057585A (en) * 2009-09-08 2011-03-24 Fancl Corp Antidepressant agent
JP2011057599A (en) * 2009-09-09 2011-03-24 Fancl Corp Energy metabolism-promoting agent
JP2011057598A (en) * 2009-09-09 2011-03-24 Fancl Corp Lipid metabolism-improving agent
JP2011057597A (en) * 2009-09-09 2011-03-24 Fancl Corp Hyperglycemic inhibitor
JP2011157343A (en) * 2010-01-05 2011-08-18 Fancl Corp Peroral anti-aging agent
JP5778912B2 (en) * 2010-01-05 2015-09-16 株式会社ファンケル IGF-1 secretion promoter
JP2011207776A (en) * 2010-03-29 2011-10-20 Fancl Corp Adiponectin production-promoting agent
JP2013071909A (en) * 2011-09-28 2013-04-22 Fancl Corp Intracerebral lipid peroxide accumulation inhibitor

Also Published As

Publication number Publication date
JP2013074821A (en) 2013-04-25

Similar Documents

Publication Publication Date Title
Fan et al. Protective properties of combined fungal polysaccharides from Cordyceps sinensis and Ganoderma atrum on colon immune dysfunction
JP5778912B2 (en) IGF-1 secretion promoter
JP5394233B2 (en) Evaluation method and screening method for substances having action to activate / inhibit innate immune mechanism, drug for activating / inhibiting innate immune mechanism, food, and production method thereof
EP4253526A1 (en) Novel bifidobacterium animalis subsp. lactis hem20-01 strain, and composition for treating depression comprising same or culture thereof
US10443033B2 (en) Lactobacillus rhamnosus RHT-3201 (KCTC 10833BP) conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases
JPWO2006093267A1 (en) Fermentation composition having immunomodulatory action
JP6443804B2 (en) Natural killer cell activity promoter
EP1674090A1 (en) Early insulin secretion promoter
JP2017081891A (en) Regulatory t cell activity compositions
JP2022113827A (en) Citrus yoko-containing composition
JP4831711B1 (en) Anti-Candida fungi and prophylactic and / or therapeutic agents for candidiasis comprising Tamogitake extract as an active ingredient
JP2011157343A (en) Peroral anti-aging agent
JP6460402B2 (en) Pharmaceutical composition or food composition for promoting cholesterol excretion
KR20120069221A (en) Bee venom composition
JP6093068B2 (en) Antibacterial peptide secretion inducer
RU2322995C1 (en) Biopreparation of veterinary indication and method for preventing gastro-intestinal diseases in neonatal calves due to its application
JP5912023B2 (en) Antibacterial peptide secretion inducer
KR102650558B1 (en) Probiotics composition for preventing, improving, or treating inflammatory disease containing Lactobacillus rhamnosus PL60 as an active ingredient
JP2007031302A (en) Adiponectin production accelerator and metabolic syndrome preventive
JP6063038B2 (en) Pharmaceutical composition containing kakukaku extract extracted at high temperature
KR101728094B1 (en) Pharmaceutical composition for preventing or treating viral diseases and cancers comprising extract or fraction from Ampelopsis brevipedunculata
JP2013147478A (en) Enteric ambience ameliorator and bowel movement ameliorator
JP2013063941A (en) Prophylactic or improving agent of irritable bowel syndrome
JP2010270104A (en) iNKT CELL ACTIVATOR
JP6209062B2 (en) Antibacterial peptide secretagogue

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160331

R150 Certificate of patent or registration of utility model

Ref document number: 5912023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250